Dave & Buster’s stock rating reiterated at Buy by Jefferies despite slower Q3 start

Benchmark has maintained a Hold rating on Dave & Buster’s stock following a disappointing Q2 performance. The company's results fell short of expectations, prompting analysts to reassess their outlook.

Editor’s Note: This matters because stock ratings can significantly influence investor decisions. A Hold rating suggests that while the stock is not a sell, it may not be a strong buy either, indicating caution among investors.

Jefferies has lowered its price target for Array Technologies from $13 to $10, indicating a less optimistic outlook for the company's stock performance.

Editor’s Note: This adjustment in the price target reflects Jefferies' concerns about Array Technologies' future growth and market conditions. Investors should pay attention to these changes as they can impact stock valuations and investment decisions.

Truist Securities has lowered the stock price target for Dave & Buster's to $22, indicating potential concerns about the company's financial outlook.

Editor’s Note: This adjustment in stock price target is significant as it reflects analysts' changing perceptions of Dave & Buster's performance, which could impact investor confidence and market behavior.

Oracle, Alphabet, and Novo Nordisk see gains in premarket trading, while Dave & Buster’s experiences a decline.

Editor’s Note: This movement in stock prices is significant as it reflects investor sentiment and market trends, which can impact overall economic conditions and individual investment strategies.

Beiersdorf has been downgraded by Jefferies due to a slowdown in Nivea sales and challenges faced by La Prairie. This decision reflects concerns about the company's growth prospects.

Editor’s Note: This matters because Beiersdorf is a major player in the skincare market, and a downgrade can impact investor confidence and stock performance. Understanding the reasons behind the downgrade helps stakeholders gauge the company's future.

Jefferies has raised its price target for Danone to €84, citing strong growth in China's nutrition sector and robust performance in protein dairy products.

Editor’s Note: This upgrade is significant as it reflects confidence in Danone's ability to capitalize on emerging markets like China, which could lead to increased investor interest and potentially higher stock prices.

L’Oréal has been downgraded by Jefferies, with the price target reduced to €340 due to a weakening growth outlook. This change reflects concerns about the company's future performance.

Editor’s Note: This downgrade is significant as it indicates potential challenges for L’Oréal in maintaining its growth trajectory. Investors and stakeholders will be closely monitoring the company's strategies to address these concerns.

Dave & Buster's reported disappointing results for Q2 2025 during their earnings call, raising concerns among investors.

Editor’s Note: This matters because disappointing earnings can affect investor confidence and stock prices, impacting the company's future growth and operations.

Dave & Buster’s shares fell 17% following disappointing Q2 results, raising concerns among investors about the company's performance.

Editor’s Note: This decline in shares is significant as it reflects investor sentiment and could impact the company's future growth and strategy. Understanding the reasons behind the disappointing results is crucial for stakeholders.

Dave & Buster’s Entertainment reported earnings that missed expectations by $0.55, with revenue also falling short of estimates. This disappointing performance raises concerns about the company's financial health.

Editor’s Note: This matters because it highlights potential challenges for Dave & Buster's in a competitive entertainment market. Investors and stakeholders will be closely watching how the company addresses these shortfalls and what strategies it will implement moving forward.

Canada's annual inflation rate in August increased, but the rise was less than analysts had anticipated. This indicates a slower pace of price growth in the economy.

Editor’s Note: Understanding inflation trends is crucial for economic planning and policy-making. A lower-than-expected rise in inflation can influence interest rates and consumer confidence, impacting overall economic health.

Soluna's stock price has surged following the announcement of a $100 million credit facility. This financial boost is expected to enhance their operational capabilities and growth potential.

Editor’s Note: This matters because securing a significant credit facility can provide Soluna with the necessary funds to expand its operations and invest in new projects, potentially leading to increased market confidence and stock value.

Luigi Mangione has successfully won the dismissal of several charges related to the killing of a US health insurance executive. This legal victory marks a significant development in his case.

Editor’s Note: This matters because it highlights the complexities of legal proceedings in high-profile cases. The dismissal of charges can impact public perception and the future of the case, potentially leading to further legal strategies.

Benchmark has maintained its 'Hold' rating on Group 1 Automotive stock, indicating a stable outlook for the company.

Editor’s Note: This rating suggests that investors should hold onto their shares rather than buying or selling, reflecting a cautious but steady view of Group 1 Automotive's performance in the market.

Benchmark has reaffirmed its Buy rating on Criteo stock, highlighting the company's partnership with Google as a key factor for growth.

Editor’s Note: This is significant because a strong partnership with Google can enhance Criteo's market position and drive future revenue, making it an attractive investment opportunity.

Aptevo Therapeutics' stock has surged following a groundbreaking trial that reported a 100% remission rate in patients with acute myeloid leukemia (AML). This remarkable achievement highlights the potential of their treatment and could significantly impact the company's future.

Editor’s Note: This news is crucial as it not only boosts Aptevo's market position but also offers hope to patients suffering from AML. A 100% remission rate is a significant milestone in cancer treatment, potentially leading to more investment and research in this area.